SOLIDAGOREN

Ukraine

The drug is used to treat acute and chronic urinary tract infections (cystitis, pyelonephritis) of mild to moderate severity as part of complex therapy, as well as to prevent the formation of bladder stones.

Brand name SOLIDAGOREN
Dosage form drops, oral
Prescription type over-the-counter (OTC)
ATC code
Registration number UA/13795/01/01
SOLIDAGOREN drops, oral

Frequently asked questions

How should Solidagoren be taken correctly?

Adults and children aged 12 years and older should take 20–30 drops 3 times a day, diluted in 100–200 ml of water. It is important to drink at least 1.5–2 liters of fluid throughout the day.

Who should not take this drug?

Contraindicated in case of hypersensitivity to the components, allergy to plants of the Asteraceae family, severe heart and kidney failure, as well as edema caused by these conditions. The drug should not be used in children under 12 years of age.

What side effects can Solidagoren cause?

Very rarely, allergic reactions or signs of hypersensitivity (e.g., rash) may occur. Mild digestive disorders are also possible.

Can the drug be combined with other medicines?

There is no precise data on interactions with other agents; however, due to the alcohol content, it may affect the action of other drugs.

Can the drug be taken during pregnancy or breastfeeding?

The use of the drug during pregnancy or breastfeeding is not recommended.

When should you contact a doctor immediately?

You should consult a specialist if blood appears in the urine, a high temperature develops, symptoms do not subside after more than 5 days, or if any side effects occur.

Instructions for use

INSTRUCTION FOR MEDICAL USE OF THE MEDICINAL PRODUCT SOLIDAGOREN® (SOLIDAGOREN®)

Composition:

Active substance: liquid extract from a mixture of the herb of giant goldenrod (Solidago gigantea Aiton) or Canadian goldenrod (Solidago canadensis L.), goosegrass cinquefoil herb (Potentilla anserina L.), and field horsetail herb (Equisetum arvense L.);

10 ml of the preparation contain 7.9 ml of liquid extract (1 : 1.5–2.1) from a mixture of the herb of giant goldenrod (Solidago gigantea Aiton) or Canadian goldenrod (Solidago canadensis L.), goosegrass cinquefoil herb (Potentilla anserina L.), and field horsetail herb (Equisetum arvense L.) (4.2 : 1.4 : 1), extracted with 50% ethanol (v/v);

Excipients: purified water, ethanol 96%.

Pharmaceutical form. Oral drops.

Main physicochemical characteristics: clear brown liquid.

Pharmacotherapeutic group.

Agents used in urology. ATC code G04B.

Pharmacological properties.

Pharmacodynamics. Studies have not been conducted.

Pharmacokinetics. Studies have not been conducted.

Clinical characteristics.

Indications.

Acute and chronic urinary tract infections (cystitis, pyelonephritis) of mild to moderate severity as part of complex therapy.

Prevention of urinary bladder stone formation, including after their removal.

Contraindications.

Hypersensitivity to the active substance or to any other component of the medicinal product. Solidago cannot be used in cases of allergy to plants of the Asteraceae family (Asteraceae), as these plants are used in the production of the herbal extract contained in the medicinal product.

Severe cardiac and renal insufficiency, edema due to cardiac and/or renal insufficiency.

Interaction with other medicinal products and other forms of interaction.

Cases of interaction with other medicinal products are unknown.

Due to the presence of ethanol in this medicinal product, an effect on the action of other drugs is possible.

Special precautions for use.

It is contraindicated to use Solidagoren as a diuretic for the treatment of edema caused by cardiac or renal insufficiency, especially in elderly patients.

If blood appears in the urine, high body temperature occurs, or if symptoms persist for more than 5 days, it is recommended to consult a physician.

The medicinal product contains 45% (v/v) ethanol. With each dose (30 drops), 0.6 g of ethanol enters the body. Therefore, this medicinal product is harmful for patients suffering from alcoholism. Caution should be exercised when administering to pregnant and breastfeeding women, children, patients with liver disorders, and patients with epilepsy.

Use during pregnancy or breastfeeding.

The medicinal product is not recommended for use during pregnancy or breastfeeding.

Ability to influence reaction rate while driving or operating machinery.

When used at recommended doses, the product does not affect reaction speed.

Dosage and Administration.

For adults and children aged 12 years and older, take orally 20–30 drops of Solidagoren with 100–200 ml of water, three times daily. 30 drops correspond to 1.4 ml of the medicinal product.

Daily fluid intake during Solidagoren treatment should be at least 1.5–2 liters.

The duration of treatment with the medicinal product is determined by a physician and depends on the course and severity of the disease. If symptoms do not improve, or if any adverse reactions occur, the use of this medicinal product must be discontinued and medical advice should be sought.

Children.

The medicinal product must not be used in children under 12 years of age.

Overdose.

No reports available. In case of overdose, adverse reactions may be intensified.

Side effects.

Very rarely, hypersensitivity reactions and allergic reactions are observed. Mild gastrointestinal disturbances are possible (frequency unknown).

If the first signs of hypersensitivity reaction occur (e.g. rash), administration of the medicinal product should be discontinued.

If adverse reactions not listed in this instruction appear, consult a physician.

Shelf life.

3 years.

After opening the bottle – 3 months.

Storage conditions.

Store at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging.

20 ml, or 50 ml, or 100 ml in a bottle with dropper; 1 bottle in a cardboard box.

Availability. Over-the-counter (without prescription).

Manufacturer.

Dr. Gustav Klein GmbH & Co. KG

Manufacturer's address and location of business activity.

Steinenfeld 3, 77736 Zell am Harmersbach, Germany.






APPROVED

Order of the Ministry of Health of Ukraine

____________ № _____

Registration Certificate

UA/13795/01/01

The original data is available in the language of the country of manufacture.

Data source: State Register of Medicinal Products of Ukraine

Data last verified: August 13, 2026